<DOC>
	<DOCNO>NCT01985763</DOCNO>
	<brief_summary>Colorectal neoplasms third common malignancy United States . Patients metastatic ( stage IV ) colorectal cancer median life expectancy 2 year . The response rate chemotherapy range 35-40 % . Epidemiologic evidence suggest soy compound may reduce incidence colorectal cancer . Laboratory analysis demonstrate genistein , soy-derived compound , may inhibit Wnt signal , pathway activated majority colorectal cancer . Laboratory observation also demonstrate genistein may augment growth inhibition combine chemotherapeutic agent 5-Fluorouracil platinum compound . Based pre-clinical data investigator hypothesize combine genistein standard care chemotherapeutic regimen reduce chemotherapy resistance improve response rate patient . The aim study add genistein regimen FOLFOX FOLFOX-Avastin patient newly diagnose stage IV colon rectal neoplasm .</brief_summary>
	<brief_title>Genistein Treatment Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate tolerability genistein combine chemotherapy Secondary : - Evaluate Response Rate ( RR ) measure radiologic RECIST criterion - Evaluate Progression Free Survival ( PFS )</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Genistein</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult male female patient ≥18 year old Have pathologically confirm colon rectal carcinoma Have metastatic ( stage IV ) disease Have plan treat physician receive FOLFOX FOLFOXAvastin Have Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 Have adequate hematopoietic , hepatic renal function 1 . Hematopoietic function Hemoglobin ≥10g/dL Absolute Neutrophil Count ( ANC ) ≥1,500cells/mm2 Platelet Count ≥100,000/µL 2 . Hepatic Function Total bilirubin ≤ 1.5x upper limit normal ALT AST must ≤2,5x upper limit normal 3 . Renal Function Estimated creatinine clearance ( Clcr ) ≥30 mL/minute Are pregnant plan become pregnant Prior systemic chemotherapy metastatic disease History breast cancer , endometrial cancer ovarian cancer take aromatase inhibitor selective estrogen receptor modulators Patients take MAOinhibitors History myocardial infarction cardiac stent placement le 1 year recruitment study Unable give inform consent comply clinical trial requirement Uncontrolled hypertension History clinically significant GI bleeding within prior 2 month prior enrollment Presence GI fistula Prior history bowel perforation History CNS thrombotic/embolic ischemic event Have past current , acute chronic concurrent medical condition/illness therapy , opinion investigator , would make subject unsuitable clinical trial unable comply follow visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Genistein</keyword>
	<keyword>soy supplement</keyword>
	<keyword>phytoestrogens</keyword>
	<keyword>colon cancer</keyword>
	<keyword>rectal cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>stage IV</keyword>
	<keyword>FOLFOX</keyword>
	<keyword>FOLFOX-Avastin</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>